Article Details
Retrieved on: 2021-06-23 12:22:30
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Tominersen was licensed to Roche, and Roche's decision to halt its phase three clinical trials was driven by lower than expected efficacy of the ...
Article found on: www.forbes.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here